Matthew W Jenner

List of Publications by Year
in descending order

73 papers	2,650 citations	236925 25 h-index	189892 50 g-index
73 all docs	73 docs citations	73 times ranked	3306 citing authors

#	Article	IF	Citations
1	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 2010, 116, e56-e65.	1.4	315
2	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 57-73.	10.7	245
3	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia, 2018, 32, 102-110.	7.2	177
4	Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood, 2006, 108, 1733-1743.	1.4	176
5	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood, 2007, 110, 3291-3300.	1.4	133
6	Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research, 2010, 16, 1856-1864.	7.0	124
7	MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica, 2009, 94, 78-86.	3.5	106
8	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia, 2017, 31, 107-114.	7.2	98
9	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. British Journal of Haematology, 2007, 137, 268-269.	2.5	96
10	Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications. Clinical Cancer Research, 2008, 14, 6033-6041.	7.0	88
11	The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica, 2007, 92, 1149-1150.	3.5	71
12	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 2016, 6, e506-e506.	6.2	68
13	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, 2020, 136, 1091-1104.	1.4	58
14	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 2010, 150, 326-333.	2.5	57
15	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 2020, 34, 604-612.	7.2	56
16	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55
17	Use of a biosimilar granulocyte colonyâ€stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. British Journal of Haematology, 2013, 162, 107-111.	2.5	50
18	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood, 2021, 137, 1154-1165.	1.4	49

#	Article	IF	Citations
19	The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide â€“ vincristine â€“ doxorubicin â€“ methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia and Lymphoma, 2006, 47, 2335-2338.	1.3	43
20	Advances in oral therapy for multiple myeloma. Lancet Oncology, The, 2006, 7, 316-325.	10.7	42
21	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	4.6	42
22	Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7777-7782.	7.1	37
23	Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.. Blood, 2007, 110, 3593-3593.	1.4	33
24	Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 2018, 132, 2465-2469.	1.4	29
25	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 2022, 40, 2889-2900.	1.6	29
26	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 2015, 64, 1021-1032.	4.2	27
27	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 2020, 34, 3091-3096.	7.2	26
28	Realâ€world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multiâ€centre <scp>UK</scp> experience. British Journal of Haematology, 2017, 176, 908-917.	2.5	25
29	Early relapse after highâ€dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically highâ€risk disease in multiple myeloma. British Journal of Haematology, 2021, 193, 551-555.	2.5	25
30	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1617-1628.	1.6	24
31	Copy number evolution and its relationship with patient outcomeâ€”an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 2021, 35, 2043-2053.	7.2	23
32	Updates to the guidelines for the diagnosis and management of multiple myeloma. British Journal of Haematology, 2014, 167, 131-133.	2.5	20
33	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	8.4	18
34	MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open, 2021, 11, e046225.	1.9	18
35	Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DTâ€PACE. European Journal of Haematology, 2008, 81, 432-436.	2.2	16
36	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, 2020, 106, haematol.2020.247130.	3.5	16

#	Article	IF	Citations
37	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 2020, Online ahead of print, 0-0.	3.5	16
38	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, openâ€label, randomised, Phase III trial. British Journal of Haematology, 2021, 192, 853-868.	2.5	14
39	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 667-675.	0.4	12
40	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 154-161.e3.	0.4	11
41	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 2022, 12, e056147.	1.9	11
42	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	1.4	10
43	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomideâ€pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European Journal of Haematology, 2022, 108, 73-83.	2.2	8
44	The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.. Blood, 2007, 110, 2727-2727.	1.4	8
45	The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).. Blood, 2006, 108, 3537-3537.	1.4	6
46	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial. Blood, 2018, 132, 3278-3278.	1.4	5
47	A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. Blood, 2019, 134, 1890-1890.	1.4	5
48	CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma. Blood, 2008, 112, 3707-3707.	1.4	4
49	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. Blood, 2015, 126, 189-189.	1.4	4
50	Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.. Blood, 2007, 110, 2494-2494.	1.4	4
51	Liposomal cytarabine in cerebrospinal fluid. British Journal of Haematology, 2009, 145, 679-679.	2.5	3
52	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Advances in Therapy, 2021, 38, 1328-1341.	2.9	2
53	Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.. Blood, 2006, 108, 112-112.	1.4	2
54	Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.. Blood, 2006, 108, 3555-3555.	1.4	2

#	Article	IF	Citations
55	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). Blood, 2016, 128, 4412-4412.	1.4	2
56	Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance. Blood, 2019, 134, 3132-3132.	1.4	1
57	Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.. Blood, 2007, 110, 395-395.	1.4	1
58	Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD.. Blood, 2006, 108, 110-110.	1.4	1
59	The Impact of Constitutional Copy Number Variants in Myeloma. Blood, 2008, 112, 496-496.	1.4	1
60	Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial. Blood, 2015, 126, 1852-1852.	1.4	1
61	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant. Blood, 2019, 134, 3120-3120.	1.4	1
62	Insights into the Basis of Chromosomal Imbalances during the Clonal Evolution of Multiple Myeloma Using SNP Array Analysis.. Blood, 2005, 106, 621-621.	1.4	0
63	Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.. Blood, 2005, 106, 1542-1542.	1.4	0
64	Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.. Blood, 2005, 106, 1563-1563.	1.4	0
65	Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.. Blood, 2006, 108, 3390-3390.	1.4	0
66	Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.. Blood, 2007, 110, 4841-4841.	1.4	0
67	Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.. Blood, 2007, 110, 2473-2473.	1.4	0
68	Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.. Blood, 2007, 110, 2474-2474.	1.4	0
69	An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.. Blood, 2007, 110, 2493-2493.	1.4	0
70	Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.. Blood, 2008, 112, 1694-1694.	1.4	0
71	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma. Blood, 2008, 112, 625-625.	1.4	0
72	XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.. Blood, 2008, 112, 1686-1686.	1.4	0

#	Article	IF	Citations
73	Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma. Blood, 2008, 112, 2725-2725.	1.4	0